RE: Quote Worth Re-Reading Over the past couple of years I have read a number of different articles all citing the need for drugs in general to be more specifically suited for various sub classes of patients with the "same" ailment. When we we look at what has occurred with the program for RVX-208 in terms of the knowledge that is being gained not only about the drug but also about the patients the drug is targeting, I would hope that the "delays" in full enrolment are due, at least in part, to increasing selectivity with respect to who is allowed to participate in the ASSURE study. I would argue that being as selective as your knowledge base allows not only gives your study a better chance of success but also serves to prove that your drug is going to usefully serve a real patient population. Later once you have a proven, useful drug you can work at broadenning it's scope. I would liken this to changing from a shotgun to a rifle.
During the 6.5 years I have been following RVX I have seen the management make some decisions that I would consider to be missteps. I am happy at this point that they seem to be taking a very calculated approach to ensure that ASSURE is a succesful trial. For me, if that means waiting a little more time to get the right group of study patients I am happy to wait, even if impatiently.